Skip to main content
Premium Trial:

Request an Annual Quote

Phase I Data Shows RXi Anti-Scarring Drug Safe, Well-tolerated

Premium

RXi Pharmaceuticals this week announced that its lead drug candidate, the anti-scarring agent RXI-109, was safe and well tolerated in a phase I study, while producing a dose-dependent reduction of its target protein.

RXI-109 comprises siRNAs designed to inhibit connective tissue growth factor, or CTGF, a protein linked to wound healing and other fibrotic processes. It employs the company's proprietary self-delivering technology, which enables cellular uptake without the need for a delivery vehicle.

In the phase I study, 15 volunteers received a single dose of the drug, at doses ranging from 0.5 mg/cm to 5 mg/cm, in two 2-centimeter areas of the abdomen. Two other areas on the abdomen were treated with placebo injections.

A day after treatment, the four areas received an incision that was immediately closed. Patients were followed for three months, at which point they underwent abdominoplasty. Samples were taken from portions of the skin removed during the surgery for assessment.

“No significant side effects or toxicity were observed and the incisions did not appear to slow healing on the active or the placebo side, indicating that RXI-109 does not delay wound closure,” RXi said. “In addition, blood level measurements for RXI-109 indicated that the maximum systemic exposure was only about 5 percent of the intradermally administered dose.”

Further, there was a statistically significant reduction in the average CTGF protein concentration in RXI-109-treated sites versus placebo sites, with the highest reduction in target protein levels observed in the incision areas receiving the two highest doses.

Data from a second, ongoing phase I study testing multiple doses of RXI-109 are expected to be available in July.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more